209 related articles for article (PubMed ID: 19198237)
1. [Pulmonary hypertension in a patient on chronic hemodialysis].
Yasuda T; Tanabe N; Konishi K; Shigeta A; Shinohara M; Toyama S; Nakamura M; Maruoka M; Tada Y; Takiguchi Y; Tatsumi K; Kuriyama T
Nihon Kokyuki Gakkai Zasshi; 2009 Jan; 47(1):52-6. PubMed ID: 19198237
[TBL] [Abstract][Full Text] [Related]
2. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Liefeldt L; van Giersbergen PL; Dingemanse J; Rudolph B; Walde T; Budde K; Neumayer HH; Hocher B
Am J Kidney Dis; 2004 May; 43(5):923-6. PubMed ID: 15112184
[TBL] [Abstract][Full Text] [Related]
3. [Primary Sjögren's syndrome with pulmonary hypertension].
Usui K; Anzai C; Sano K; Kumazaki S; Ishihara T
Nihon Kokyuki Gakkai Zasshi; 1998 May; 36(5):478-81. PubMed ID: 9742868
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension.
Chen CH; Chen HA; Yang KY; Yu WC; Liao HT; Huang DF
Scand J Rheumatol; 2006; 35(3):245-7. PubMed ID: 16766376
[No Abstract] [Full Text] [Related]
5. Bosentan improved syncope in a hemodialysis patient with pulmonary hypertension and mild aortic stenosis.
Yamanaka A; Tasaki H; Suzuki Y; Tanaka S; Yamashita K; Tamura M; Abe H; Otsuji Y
Int Heart J; 2006 Nov; 47(6):911-7. PubMed ID: 17268125
[TBL] [Abstract][Full Text] [Related]
6. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
8. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal of epoprostenol therapy in a patient with pulmonary hypertension associated with Sjögren's syndrome.
Fujita T; Tanabe N; Kasahara Y; Sugiura T; Sakao S; Tatsumi K
Intern Med; 2014; 53(19):2237-40. PubMed ID: 25274237
[TBL] [Abstract][Full Text] [Related]
10. Association of Intraocular Pressure Changes With Right Ventricular Diameter and Brain Natriuretic Peptide in a Case of Pulmonary Arterial Hypertension.
Sato C; Kaneko H; Kondo T; Takayama K; Yasuda S; Terasaki H
J Glaucoma; 2016 Mar; 25(3):e295-8. PubMed ID: 26796310
[TBL] [Abstract][Full Text] [Related]
11. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
12. Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report.
Santos JR; Merino A; Haefeli WE; Miranda C; Prats M; Bancu I; Bailón L; Moltó J
BMC Nephrol; 2020 Jan; 21(1):24. PubMed ID: 31992232
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
[TBL] [Abstract][Full Text] [Related]
14. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.
Fukuda Y; Miura S; Fujimi K; Yano M; Nishikawa H; Yanagisawa J; Hiratsuka M; Shiraishi T; Iwasaki A; Saku K
Eur J Prev Cardiol; 2014 Dec; 21(12):1481-3. PubMed ID: 23897898
[TBL] [Abstract][Full Text] [Related]
16. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
[TBL] [Abstract][Full Text] [Related]
17. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
[TBL] [Abstract][Full Text] [Related]
18. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
Ibrahim R; Granton JT; Mehta S
Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S
Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
